Protocol Ledger

NCT04282109 · Phase II · COMPLETED

Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)

Interventional Phase II clinical trial protocol NCT04282109 sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-06-03 Enrollment: 141 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04282109
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)141 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04282109
Protocol FieldVerified Registry Value
NCT IdentifierNCT04282109
Consolidated Lead SponsorGrupo Español de Tratamiento de Tumores de Cabeza y Cuello
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment141 participants (ACTUAL)
Registered Start Date2020-06-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI